Heron Therapeutics (HRTX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics, Inc. announced on January 23, 2024, that the FDA approved the expanded use of ZYNRELEF® (bupivacaine and meloxicam) for soft tissue and orthopedic surgical procedures, specifically excluding those involving direct exposure to articular cartilage.
For further insights into HRTX stock, check out TipRanks’ Stock Analysis page.